205643-28-3

Usage

Uses

Used in Pharmaceutical Research:
1H-Indazole, 3-iodo-1-(phenylmethyl)is used as a potential drug candidate in pharmaceutical research for the development of new psychoactive and therapeutic agents. Its unique structure and properties make it a promising candidate for further exploration and study.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1H-Indazole, 3-iodo-1-(phenylmethyl)is employed for the synthesis and modification of various compounds with potential medicinal applications. Its ability to be easily modified and its unique chemical properties make it a valuable tool for researchers in this field.
Used in Drug Discovery:
1H-Indazole, 3-iodo-1-(phenylmethyl)is used in drug discovery processes to identify and develop new compounds with therapeutic potential. Its unique structure and properties may contribute to the discovery of novel drugs with improved efficacy and safety profiles.
Used in Neuropharmacology:
In neuropharmacology, 1H-Indazole, 3-iodo-1-(phenylmethyl)is used to study the effects of psychoactive substances on the central nervous system. Its potential as a psychoactive agent makes it a valuable tool for understanding the mechanisms of action and developing new treatments for neurological disorders.
Note: The specific applications and industries for 1H-Indazole, 3-iodo-1-(phenylmethyl)may vary depending on the research and development progress. The uses listed above are based on the general potential of the compound in various fields of study. Further research and development may reveal additional applications and industries where 1H-Indazole, 3-iodo-1-(phenylmethyl)- can be effectively utilized.

Upstream product

• 66607-27-0 3-iodoindazole 
• 100-39-0 benzyl bromide 
• 741693-32-3 1-benzyl-3-trimethylsilylindazole 
• 679794-95-7 3-trimethylsilylindazole 
• 271-44-3 benzimidazole 

Downstream Products

• 232935-04-5 1-benzyl-3-(furan-2-yl)-1H-indazole 
• 170632-13-0 1-benzyl-3-(5-methoxycarbonyl-furan-2-yl)-1H-indazole 
• 170632-47-0 1-benzyl-3-(5-hydroxymethyl-2-furyl)indazole 
• 205643-02-3 1-Benzyl-3-[5-(1,3-dioxolan-2-yl)-furan-2-yl]-indazole 
• 205646-21-5 1-benzyl-3-trimethylstannylindazole 
• 1186509-61-4 1-benzyl-1H-indazole-3-carbaldehyde 
• 131427-21-9 (1-Benzyl-1H-indazol-3-yl)-methanol 
• 131427-22-0 1-benzyl-3-chloromethyl-1H-indazole 
• 130641-38-2 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid 
• 205646-24-8 1-benzyl-1H-indazole-3-carbonitrile 
• 170632-42-5 1-benzyl-3-(5'-hydroxycarbonyl-2'-furyl)indazole 
• 865757-06-8 succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl]ester 
• 849330-91-2 [5-(1-benzyl-1H-indazol-3-yl)-tetrahydro-furan-2-yl]methanol 
• 849330-87-6 [5-(1-benzyl-1H-indazol-3-yl)-1-methyl-1H-pyrrol-2-yl]methanol 

Relevant academic research and scientific papers

Hypoxia-Targeting Organometallic Ru(II)-Arene Complexes with Enhanced Anticancer Activity in Hypoxic Cancer Cells

As hypoxia is an important factor to limit chemotherapeutic efficacy in tumors, we herein report three ruthenium(II)-arene complexes containing a hypoxia inducible factor-1α inhibitor (YC-1), which endow the organometallic complexes with potential for hyp

The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents

1-Benzyl-3-(substituted aryl)-5-methylfuro[3,2-c]pyrazole (YC-1) is a well-known synthetic compound with various satisfactory pharmacological activities, such as the activation of soluble guanylate cyclase (sGC) and the inhibition of hypoxia-induced facto

ANTI-ANGIOGENESIS COMPOUNDS

The present invention provides methods and pharmaceutical compositions for inhibiting expressions of HIF and HIF regulated genes, inhibiting angiogenesis, inducing cell cycle arrest in tumor cells, and treating cell proliferating diseases or conditions

COMPOUNDS, COMPOSITIONS AND METHODS

The present invention provides methods and pharmaceutical compositions for inhibiting expressions of HIF and HIF regulated genes, inhibiting angiogenesis, inducing cell cycle arrest in tumor cells, and treating cell proliferating diseases or conditions.

New synthesis of 3-substituted indazoles from 3-trimethylsilylindazole

Reaction of aryl aldehydes with 3-trimethylsilylindazole in the presence of CsF easily gave the corresponding 3-(arylhydroxymethyl)indazoles in good to moderate yields.

Blockade of voltage dependent sodium channels

Compounds of formula (1), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.

Heck cross-couplingg reaction of 3-iodoindazoles with methyl acrylate: A mild and flexible strategy to design 2-azatryptamines

In order to design 2-azabioisosteres of tryptamine, serotonin or melatonin, the conditions of the Heck coupling reaction of 3-iodoindazoles with methyl acrylate are studied. This reaction authorizes the synthesis of 3-indazolylpropenoates as key intermediates to prepare 3-indazolylpropionic acids and 3-indazolylethylamines. The flexible synthetic strategy allows molecular diversity. (C) 2000 Elsevier Science Ltd.

Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases

PCT No. PCT/EP97/05432 Sec. 371 Date Apr. 9, 1999 Sec. 102(e) Date Apr. 9, 1999 PCT Filed Oct. 2, 1997 PCT Pub. No. WO98/16507 PCT Pub. Date Apr. 23, 1998The present invention relates to new heterocyclylmethyl-substituted pyrazole derivatives, processes f

Suzuki-type cross-coupling reaction of 3-iodoindazoles with aryl boronic acids: A general and flexible route to 3-arylindazoles

This paper describes a Suzuki Type cross coupling reaction of 3- iodoindazoles with aryl and heteroaryl boronic acids as a general route to 3- arylindazoles. The coupling reaction is illustrated by the preparation of new aryl- or heteroarylindazoles 7. Scope and limitation of the method are outlined. The coupling reaction works best on a 1-substituted indazole nucleus. The usefulness of the reaction is illustrated by a short practical synthesis of YC-1, a pharmacological agent potentially useful for the treatment of cardiovascular diseases or erectile dysfunction.